Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Adam R. Craig, Executive Chairman of X4 Pharmaceuticals Inc (NASDAQ:XFOR), acquired 86,206 shares of the company’s common stock on October 23, 2025. The shares were purchased at a price of $2.90, for a total transaction value of $249,997. The stock, which InvestingPro data shows has fallen nearly 80% over the past year, is currently trading at $3.74, representing a 29% gain from Craig’s purchase price.
The purchase is connected with the issuer’s public offering. Following the transaction, Craig directly owns 376,087 shares of X4 Pharmaceuticals, Inc., showing confidence in the company despite its rapid cash burn rate. InvestingPro analysis indicates the stock is currently undervalued, with analysts setting price targets ranging from $3.50 to $14.00. Get deeper insights with InvestingPro’s comprehensive research report, available for over 1,400 US stocks.
In other recent news, X4 Pharmaceuticals has announced a public offering of 45,860,000 shares of its common stock at a price of $2.90 per share, along with pre-funded warrants for 700,000 shares priced at $2.899 each. This offering is expected to generate approximately $135 million in gross proceeds, with the funds earmarked for the pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders and general corporate expenses. The underwriters, including Leerink Partners LLC, Stifel, Nicolaus & Company, and Guggenheim Securities, have exercised their option to purchase an additional 6,984,000 shares. Additionally, X4 Pharmaceuticals has announced a strategic restructuring plan, which includes a 50% reduction in its workforce, aiming to save approximately $13 million annually. Leadership changes accompany this restructuring, with John Volpone taking on the role of Chief Operating Officer while maintaining his position as President. Meanwhile, Altimmune has appointed Dr. Christophe Arbet-Engels as the new Chief Medical Officer to lead the clinical development of pemvidutide. Dr. Arbet-Engels will oversee the planned Phase 3 trial for metabolic dysfunction-associated steatohepatitis, succeeding Dr. Scott Harris, who will remain as a Senior Strategic Advisor until 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.